Ensong Guo

568 total citations
9 papers, 311 citations indexed

About

Ensong Guo is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ensong Guo has authored 9 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Immunology. Recurrent topics in Ensong Guo's work include PARP inhibition in cancer therapy (3 papers), CRISPR and Genetic Engineering (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ensong Guo is often cited by papers focused on PARP inhibition in cancer therapy (3 papers), CRISPR and Genetic Engineering (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ensong Guo collaborates with scholars based in China, Nepal and United States. Ensong Guo's co-authors include Chaoyang Sun, Gang Chen, Jia Huang, Rourou Xiao, Junbo Hu, Xiaoyan Xu, Meng Xia, Dianxing Hu, Ding Ma and Xu Qin and has published in prestigious journals such as Cancer Research, Scientific Reports and Acta Biomaterialia.

In The Last Decade

Ensong Guo

9 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ensong Guo China	9	220	91	62	37	37	9	311
Rourou Xiao China	10	168 0.8×	114 1.3×	67 1.1×	36 1.0×	31 0.8×	17	330
Yiran Wang China	9	138 0.6×	104 1.1×	149 2.4×	14 0.4×	47 1.3×	22	325
Carolyn M. Ray United States	6	98 0.4×	102 1.1×	49 0.8×	100 2.7×	38 1.0×	8	296
Lili Ge China	12	230 1.0×	52 0.6×	48 0.8×	43 1.2×	112 3.0×	34	371
Jifeng Liu China	11	96 0.4×	36 0.4×	41 0.7×	29 0.8×	31 0.8×	18	296
Dianxing Hu China	7	96 0.4×	39 0.4×	21 0.3×	15 0.4×	16 0.4×	11	148
Weiru Wu China	11	252 1.1×	30 0.3×	51 0.8×	5 0.1×	26 0.7×	16	396
R. De Leo Italy	9	104 0.5×	56 0.6×	26 0.4×	124 3.4×	14 0.4×	19	340
Samantha Yiling Quah Singapore	11	334 1.5×	70 0.8×	103 1.7×	4 0.1×	61 1.6×	12	530
Xianping Ding China	14	229 1.0×	37 0.4×	44 0.7×	135 3.6×	43 1.2×	55	508

Countries citing papers authored by Ensong Guo

Since Specialization

Citations

This map shows the geographic impact of Ensong Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ensong Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ensong Guo more than expected).

Fields of papers citing papers by Ensong Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ensong Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ensong Guo. The network helps show where Ensong Guo may publish in the future.

Co-authorship network of co-authors of Ensong Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Ensong Guo. A scholar is included among the top collaborators of Ensong Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ensong Guo. Ensong Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Wang, Wei, Yuxuan Xiong, Funian Lu, et al.. (2022). Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity. Acta Biomaterialia. 157. 428–441. 17 indexed citations

2.

Wang, Zizhuo, Xu Qin, Dianxing Hu, et al.. (2022). Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer. Cell Reports. 41(13). 111890–111890. 50 indexed citations

3.

Yang, Bin, Xi Li, Yu Fu, et al.. (2021). MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Research. 81(10). 2714–2729. 38 indexed citations

4.

Wu, Xue, Xiaoyan Kang, Xiaoxiao Zhang, et al.. (2021). WEE1 inhibitor and ataxia telangiectasia and RAD3‐related inhibitor trigger stimulator of interferon gene‐dependent immune response and enhance tumor treatment efficacy through programmed death‐ligand 1 blockade. Cancer Science. 112(11). 4444–4456. 20 indexed citations

5.

Li, Fuxia, Ensong Guo, Jia Huang, et al.. (2020). mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers.. American Journal of Cancer Research. 10(3). 908–924. 14 indexed citations

6.

Zhou, Bo, Meng Xia, Bin Wang, et al.. (2019). Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo. Journal of Ovarian Research. 12(1). 107–107. 15 indexed citations

7.

Zhou, Bo, Chaoyang Sun, Jia Huang, et al.. (2019). The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. Scientific Reports. 9(1). 1691–1691. 114 indexed citations

8.

Zhao, Haiyue, Ensong Guo, Ting Hu, et al.. (2016). KCNN4andS100A14act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. Oncotarget. 7(28). 43924–43938. 24 indexed citations

9.

Lu, Hao, Chaoyang Sun, Bo Zhou, et al.. (2016). HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 23(3). 119–128. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact